A world-class specialty pharmaceutical company
Our ambition is to become a leading specialty pharmaceutical company meeting the needs of patients around the world. With our portfolio of respiratory products we’re making good progress towards achieving our goal.
Press Releases
- Circassia Announces Successful Completion of FDA Pre-submission Meeting for Novel Nitric Oxide Product AirNOvent
- Circassia to Acquire US and Chinese Commercialisation Rights to Novel Nitric Oxide Product AirNOvent from AIT Therapeutics Inc.
- Circassia to Exercise Option for Full US Commercial Rights to COPD Treatment Tudorza® from AstraZeneca
